amiodarone and atorvastatin

Amiodarone inhibits the cytochrome P450 isoenzyme CYP3A4, which is the primary enzyme responsible for the metabolism of atorvastatin. This inhibition reduces the clearance of atorvastatin, leading to increased plasma concentrations. Amiodarone may also inhibit P-glycoprotein, an efflux transporter that limits intestinal absorption and biliary excretion of atorvastatin, further contributing to elevated systemic exposure.

The combination can result in elevated atorvastatin levels, increasing the risk of dose-dependent adverse effects, particularly myopathy and rhabdomyolysis. Patients may present with muscle pain, tenderness, weakness, and elevated creatine kinase levels. The risk is higher when amiodarone is initiated or the atorvastatin dose is increased.

Avoid co-prescribing high-dose atorvastatin with amiodarone. If combination is necessary, use the lowest effective dose of atorvastatin (e.g., starting at 10 mg/day) and monitor for signs of myopathy. Counsel the patient to report unexplained muscle pain or weakness. Measure creatine kinase at baseline and if symptoms develop. Consider alternative lipid-lowering therapy (e.g., pravastatin or rosuvastatin, which are less dependent on CYP3A4) where possible.

The interaction is well documented in case reports and pharmacokinetic studies, and guidelines recommend caution when combining CYP3A4 inhibitors with statins.